Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEO-TIM: Neoadjuvant Plus Adjuvant Therapy in High-risk Resectable Melanoma
NCT04722575Phase 2Active, not recruiting
- Start
- Dec 2020
- Primary completion
- Dec 2023
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab, cobimetinib, vemurafenib in melanoma. Started Dec 2020; status: active, not recruiting.
02
Drugs
atezolizumabcobimetinibvemurafenib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04722575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04722575.